{"id":200407,"name":"HERON THERAPEUTICS, INC.","slug":"heron-therapeutics-inc","state":"CA","description":"&#226;€‹Pharmaceutical company","totalSpending":1640000,"filings":33,"yearlySpending":[{"year":2018,"income":240000},{"year":2019,"income":200000},{"year":2020,"income":150000},{"year":2021,"income":250000},{"year":2022,"income":200000},{"year":2023,"income":200000},{"year":2024,"income":200000},{"year":2025,"income":200000}],"firms":["FARRAGUT PARTNERS LLP"],"lobbyists":["JEFF MACKINNON","JOSEPH VASAPOLI","JEFFERY MORTIER","JODY GALE","SARAH WALTER","J WALSH","EDWARD WHITFIELD","KRISTEN O'NEILL","WILLIAM KRIEGER","KRISTEN BAUTZ","DYLAN MOORE","CONSTANTINE HINGSON"],"issues":["PHA","HCR","MMM",null],"sampleDescriptions":["Issues related to opioid epidemic/specifically modifying rate setting for post surgical non opiods.","Issues related to opioids. Medicare coverage decisions.","Medicare coverage decisions.","Issues related to opioid epidemic/specifically modifying rate setting for post surgical non opioids. Work on HR 5809","Issues related to opioids-specifically modifying rate setting policies at CMS. Medicare coverage decisions.","Issues related to opioids specifically\nmodifying rate setting policies at CMS. Medicare coverage decisions.","Issues related to opioids specifically\nmodifying rate setting policies at CMS. Medicare coverage decisions. FDA guidance","Issues related to opioids specifically \nmodifying rate setting policies at CMS. Medicare coverage decisions. FDA guidance","Issues related to non-opioid alternatives reimbursement. Coverage decisions related to anti nausea treatments. Federal non-opioid directive legislation"],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}